Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar plus platinum-based doublet as first-line therapy in driver gene-negative advanced NSCLC
ChiCTR2100042088Phase 4Recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of endostar in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Progression-free survival. Started Feb 2021; status: recruiting.
02
Drugs
endostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100042088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042088.